The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 401–500 of 849
Kandukuri, J., Yu, S., Cheng, B., Bandi, V., D'Souza, F. W., Nguyen, K. T., Hong, Y., & Yuan, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020323 · Cited by 17
Abdel-Rahman, O. M., Ghosh, S., & Walker, J. W. T. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02301-1 · Cited by 17
Panitumumab safety for treating colorectal cancer
Stremitzer, S., Sebio, A., Stintzing, S., & Lenz, H. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.915024 · Cited by 17
WINDOW consortium: A path towards increased therapy efficacy against glioblastoma
Abdul, K., Houweling, M., Svensson, F., Narayan, R. S., Cornelissen, F. M. G., Küçükosmanoğlu, A., Metzakopian, E., Watts, C., Bailey, D. S., Würdinger, T., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.001 · Cited by 16
A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours
Macpherson, I. R., Poondru, S., Simon, G. R., Gedrich, R. W., Brock, K., Hopkins, C. A., Stewart, K., Stephens, A. W., & Evans, T. R. J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.036 · Cited by 16
Dual EGFR Inhibition in combination with anti-VEGF treatment in colorectal cancer
Falchook, G. S., Naing, A., Wheler, J. J., Tsimberidou, A. M., Zinner, R., Hong, D. S., Fu, S., Piha-Paul, S. A., Jankú, F., Hess, K. R., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.73 · Cited by 16
Trends in Phase II Trials for Cancer Therapies
Azam, F., & Vázquez, A. (2021) · Cancers · doi:10.3390/cancers13020178 · Cited by 16
Targeted Drug Therapies and Cancer
Yim, K.-L., & Cunningham, D. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-03503-6_10 · Cited by 16
Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?
Govaert, K. M., van Kessel, C. S., Lolkema, M. P., Ruers, T. J. M., & Rinkes, I. H. M. B. (2012) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0122-9 · Cited by 15
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
Fuloria, J. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s31412 · Cited by 16
The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer
Fakih, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.20 · Cited by 17
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
Rohrberg, K. S., Olesen, R. K., Pfeiffer, P., Ladekarl, M. B., Pappot, H., Christensen, I. J., Høyer‐Hansen, G., Mau‐Sørensen, M., Skov, B. G., Buysschaert, I., et al. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.619568 · Cited by 16
Nie, F., Shen, J., Tong, J. L., Xi Tao, X. U., Zhu, M., & Ran, Z. H. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00393.x · Cited by 16
Emerging combination therapies to overcome resistance in EGFR-driven tumors
Ratti, M., & Tomasello, G. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000035 · Cited by 15
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 16
Targeted therapy in advanced colorectal cancer: more data, more questions
Ochenduszko, S. L., & Krzemieniecki, K. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833cfc99 · Cited by 15
Anti-vascular endothelial growth factor therapy in the era of personalized medicine
Féliz, L. R., & Tsimberidou, A. M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2124-y · Cited by 15
Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview
Fan, Y. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0510 · Cited by 17
Perez, K. J., Walsh, R. J., Brilliant, K. E., Noble, L. C., Yakirevich, E., Breese, V., Jackson, C. L., Chatterjee, D. N., Pricolo, V. E., Roth, L. A., et al. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.01.004 · Cited by 15
Stein, A., Petersen, V., Schulze, M., Seraphin, J., Hoeffkes, H., Valdix, A., Schroeder, J., Herrenberger, J., Boxberger, F., Leutgeb, B., et al. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.961649 · Cited by 15
Burzykowski, T., Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Bokemeyer, C., Díaz‐Rubio, E., Douillard, J., Falcone, A., Fuchs, C. S., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11750 · Cited by 15
Self-citationIncorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer
Papadimitriou, K., Rolfo, C. D., Dewaele, E., van de Wiel, M., den Brande, J. V., Altıntaş, S., Huizing, M. T., Specenier, P. M., & Peeters, M. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0333-9 · Cited by 15
Marshall, J. L. (2009) · Journal of Oncology · doi:10.1155/2009/937305 · Cited by 15
Self-citationCabebe, E. C., Fisher, G. A., & Sikic, B. I. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9656-y · Cited by 15
Bonomi, P., Mace, J. R., Mandanas, R. A., Min, M., Olsen, M. R., Youssoufian, H., Katz, T. L., Sheth, G. R., & Lee, H. J. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318282ded5 · Cited by 15
Targeted Therapies in Epithelial Ovarian Cancer
Dean, E. J., El-Helw, L., & Hasan, J. (2010) · Cancers · doi:10.3390/cancers2010088 · Cited by 15
Expert consensus on maintenance treatment for metastatic colorectal cancer in China
Xu, R., Shen, L., Li, J., Xu, J.-M., Bi, F., Ba, Y., Bai, L., Shu, Y., Liu, T.-S., Li, Y.-H., et al. (2016) · 癌症：英文版 · doi:10.1186/s40880-015-0067-x · Cited by 15
Price, T. J., Segelov, E., Burge, M., Haller, D. G., Tebbutt, N. C., Karapetis, C. S., Punt, C. J. A., Pavlakis, N., Arnold, D., Gibbs, P., et al. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.949678 · Cited by 13
He, J., Liu, Y., Liu, C., Hu, H., Sun, L., Xu, D., Li, J., Wang, J., Chen, X., Lin, R., et al. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231152350 · Cited by 14
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
Berardi, R. (2010) · Core evidence · doi:10.2147/ce.s7035 · Cited by 14
Angiogenesis-related molecular targets in esophageal cancer
Hong, L., Li, S., Han, Y., Du, J., Zhang, H., Li, J., Zhao, Q., Wu, K., & Fan, D. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.571203 · Cited by 14
Stec, R., Bodnar, L., Smoter, M., Ma̧czewski, M., & Szczylik, C. A. (2010) · Oncology Letters · doi:10.3892/ol.2010.212 · Cited by 14
Tebbutt, N. C., Kotasek, D., Burris, H. A., Schwartzberg, L. S., Hurwitz, H. I., Stephenson, J., Warner, D. J., Chen, L., Hsu, C., & Goldstein, D. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2694-y · Cited by 14
Toi, M., Saeki, T., Iwata, H., Inoue, K., Tokuda, Y., Sato, Y., Ito, Y., Aogi, K., Takatsuka, Y., & Arioka, H. (2012) · Breast Cancer · doi:10.1007/s12282-012-0344-3 · Cited by 14
Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer
Lo, L. L., Patel, D., Townsend, A. R., & Price, T. J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1112787 · Cited by 14
Taniguchi, H., Komori, A., Narita, Y., Kadowaki, S., Ura, T., Andoh, M., Yatabe, Y., Komori, K., Kimura, K., Kinoshita, T., et al. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv193 · Cited by 14
Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
Ridouane, Y., Lopes, G. D. L., Jr., Ku, G. Y., Masud, H., & Haaland, B. A. (2017) · Oncotarget · doi:10.18632/oncotarget.20185 · Cited by 13
Chinese consensus on prevention of colorectal neoplasia (2021, S hanghai)
Fang, J.-Y. (2022) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13079 · Cited by 14
Jouan–Hureaux, V., Boura, C., Merlin, J., & Faivre, B. (2011) · Microvascular Research · doi:10.1016/j.mvr.2011.07.008 · Cited by 14
Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms
Bellizzi, A. M. (2013) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2013.11.001 · Cited by 14
Li, X., Shan, B.-E., Wang, J., Xing, L., Guo, X.-J., Zhang, Y.-H., Shi, P.-H., & Wang, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081897 · Cited by 14
ACR Appropriateness Criteria®: Rectal Cancer—Metastatic Disease at Presentation
Herman, J. M., Messersmith, W. A., Suh, W. W., Blackstock, W. A., Cosman, B. C., Mohiuddin, M., Poggi, M. M., Regine, W. F., Saltz, L. B., Small, W. C., et al. (2010) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2010.04.006 · Cited by 14
Tumor Vasculature as a Therapeutic Target in Non-small Cell Lung Cancer
Bar, J., & Goss, G. D. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182435f3e · Cited by 14
A strategic revolution in HIV and global health.
England, R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61119-7 · Cited by 5
Targeted biotherapy in metastatic colorectal carcinoma: Current practice
Cacheux, W., Tourneau, C. L., Baranger, B., Mignot, L., & Mariani, P. (2011) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2010.12.004 · Cited by 14
Optimal Management of Metastatic Colorectal Cancer
McRee, A. J., & Goldberg, R. M. (2011) · Drugs · doi:10.2165/11591770-000000000-00000 · Cited by 13
Simonelli, M., Zucali, P. A., Lorenzi, E., Rubino, L., Vincenzo, F. D., Sanctis, R. D., Perrino, M., Mancini, L. L., Tommaso, L. D., Rimassa, L., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.016 · Cited by 13
Corti, D., & Kearns, J. D. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.001 · Cited by 13
Antiangiogenic drugs in ovarian cancer
Markman, M. M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903120907 · Cited by 13
Visentin, M., Biason, P., & Toffoli, G. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.005 · Cited by 13
Larsen, F. O., Pfeiffer, P., Nielsen, D. L., Skougaard, K., Qvortrup, C., Vistisen, K. K., Fromm, A.-L., Jørgensen, T. L., Bjerregaard, J. K., Høgdall, E. V. S., et al. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.546369 · Cited by 13
Krawczyk, P. A., & Kowalski, D. M. (2014) · Współczesna Onkologia · doi:10.5114/wo.2013.38566 · Cited by 13
Biomarkers in Colorectal Cancer
Lim, H. Y., & Toh, H. C. (2011) · Proceedings of Singapore Healthcare · doi:10.1177/201010581102000105 · Cited by 13
Schmoll, H., Mann, J., Meinert, F. M., Garlipp, B., Borchert, K., Vogel, A., Goekkurt, E., Kaiser, U., Hoeffkes, H., Rüssel, J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02496-4 · Cited by 13
The Role of Cetuximab in the Management of Non–Small-Cell Lung Cancer
Owonikoko, T. K., Sun, S., & Ramalingam, S. S. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.031 · Cited by 12
Farshid, G., Armes, J. E., Bell, R. H., Cummings, M. C., Fox, S. B., Francis, G. D., Haswell, M., Morey, A. L., McCue, G., Raymond, W. A., et al. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181e1cc9d · Cited by 12
Cartwright, T. H. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.12.001 · Cited by 12
Michael, M., Zalcberg, J. R., Gibbs, P., Lipton, L. R., Gouillou, M., Jefford, M., McArthur, G. A., Copeman, M. C., Lynch, K., & Tebbutt, N. C. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2009-5 · Cited by 12
Tumor biology and cancer therapy – an evolving relationship
Seufferlein, T. T. W., Ahn, J., Krndija, D., Lother, U., Adler, G., & von Wichert, G. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-19 · Cited by 12
Aprile, G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8474 · Cited by 11
Future of targeted agents in metastatic colorectal cancer
Burotto, M., Hartley, M. L., Marshall, J. L., & Pishvaian, M. J. (2012) · Colorectal Cancer · doi:10.2217/crc.12.52 · Cited by 12
Self-citationXu, W. D., Gong, Y., Kuang, M., Wu, P., Cao, C., Chen, J., & Tang, C. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0465-0 · Cited by 13
Emerging Treatments in Recurrent and Metastatic Colorectal Cancer
Ciombor, K. K., & Bekaii‐Saab, T. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0217 · Cited by 11
Vaidyanathan, G., Groman, A. E., Wilding, G. E., & Fakih, M. (2010) · Oncology · doi:10.1159/000319549 · Cited by 12
Two-in-One Designer Antibodies
Parren, P. W. H. I., & Burton, D. R. (2009) · Science · doi:10.1126/science.1172253 · Cited by 12
Cetuximab in first line treatment of metastatic colorectal cancer
Barone, C. A., Belisari, A., Ciardiello, F., Mantovani, L. G., D’Angiolella, L. S., Furneri, G., Normanno, N., Piacentini, P., & Pinto, C. (2012) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v13i1s.305 · Cited by 12
Ren, L., Zhu, D., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, R., Ye, Y., Zhang, S., et al. (2023) · Clinical Surgical Oncology · doi:10.1016/j.cson.2023.100013 · Cited by 11
Komorowski, A. S., MacKay, H. J., & Pezo, R. C. (2020) · Cancer Medicine · doi:10.1002/cam4.3095 · Cited by 11
Lv, Y., Yang, Z., Zhao, L., Zhao, S., Han, J., & Zheng, L. (2015) · Europe PMC (PubMed Central) · Cited by 11
Immunotherapy for treating metastatic colorectal cancer
Boghossian, S., Robinson, S. M., von Delwig, A. A., Manas, D., & White, S. A. (2011) · Surgical Oncology · doi:10.1016/j.suronc.2010.10.004 · Cited by 11
Rosa, B. R., de Jesus, J. P., de Mello, E. L., Cesar, D. S., & Correia, M. M. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.582 · Cited by 11
Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
Bekaii‐Saab, T., Bupathi, M., & Ahn, D. H. (2016) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s97740 · Cited by 13
Passardi, A., Scarpi, E., Gelsomino, F., Palladino, M. A., Gardini, A. C., Turci, D., Chiurì, V. E., Mucciarini, C., Tassinari, D., Ragazzini, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11048-9 · Cited by 11
Tehfe, M. A., Tabchi, S., Laterza, M. M., & Vita, F. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0434 · Cited by 11
Epidermal growth factor receptor and metastatic colorectal cancer: Insights into target therapies
de Mello, R. A. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i38.6315 · Cited by 11
Spotlight on Panitumumab in Metastatic Colorectal Cancer†
Keating, G. M. (2010) · BioDrugs · doi:10.2165/11205460-000000000-00000 · Cited by 11
Targeted therapy in gastrointestinal malignancies
Iyer, R. V., Chhatrala, R., & Thanavala, Y. M. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.127639 · Cited by 11
Systemic treatment of liver metastases from colorectal cancer
Stein, A., & Schmoll, H. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012473347 · Cited by 11
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
Lipsyc-Sharf, M. D., Ou, F., Yurgelun, M. B. B., Rubinson, D. A., Schrag, D., Dakhil, S. R., Stella, P. J., Weckstein, D. J., Wender, D. B., Faggen, M. G., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab025 · Cited by 12
Self-citationLam, K. O., Lee, V. H.-F., LIU, R. K. Y., Leung, T., & Kwong, D. L. �. (2012) · Oncology Letters · doi:10.3892/ol.2012.1045 · Cited by 10
Sogabe, S., Komatsu, Y., Yuki, S., Kusumi, T., Hatanaka, K., Nakamura, M., Kato, T., Miyagishima, T., Hosokawa, A., Iwanaga, I., et al. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr008 · Cited by 10
Multigene Assays in Metastatic Colorectal Cancer
Deeb, K. K., Sram, J. P., Gao, H., & Fakih, M. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0221 · Cited by 10
Lawler, M., Johnston, B., Schaeybroeck, S. V., Salto‐Tellez, M., Wilson, R. H., Dunlop, M. G., & Johnston, P. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00074-8 · Cited by 10
Höchster, H. S., Catalano, P. J., Weitz, M., Mitchell, E., Cohen, D. J., O'Dwyer, P. J., Faller, B. A., Kortmansky, J. S., O’Hara, M. H., Kricher, S. M., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae114 · Cited by 10
Self-citationHecht, J. R., Mitchell, E., Yoshino, T., Welslau, M., Lin, X., Maneval, E. C., Paolini, J., Lechuga, M. J., & Kretzschmar, A. (2015) · Cancer Management and Research · doi:10.2147/cmar.s61408 · Cited by 10
Self-citationMúñoz, A., Pericay, C., Girón, C. G., Alonso, V., Dueñas, R., Cirera, L., Rivera, F., Falcó, E., Álvarez, I., & Salud, A. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504014x13887748696743 · Cited by 10
Chong, G., & Tebbutt, N. C. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010375096 · Cited by 10
New Trends in Epidermal Growth Factor Receptor-Directed Monoclonal Antibodies
Markman, B., Capdevila, J., Élez, E., & Tabernero, J. M. (2009) · Immunotherapy · doi:10.2217/imt.09.66 · Cited by 10
Combination Agents Versus Multi-Targeted Agents – Pros and Cons
Monzon, J. G., & Dancey, J. E. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00155 · Cited by 10
Liver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases
Kemeny, N. E., Kurilova, I., Li, J., Camacho, J. C., & Sofocleous, C. T. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02284-9 · Cited by 10
Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions
Chen, H. X., Cleck, J. N., Coelho, R. P., & Dancey, J. E. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.10.002 · Cited by 10
Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer
Cripps, C., Gill, S., Ahmed, S., Colwell, B., Dowden, S. D., Kennecke, H. F., Maroun, J. A., Samson, B., Thirlwell, M. P., & Wong, R. P. W. (2010) · Current Oncology · doi:10.3747/co.v17i6.670 · Cited by 10
Kumachev, A., Yan, M., Berry, S. R., Ko, Y., Martínez, M. C. R., Shah, K. T., & Chan, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140187 · Cited by 10
Zhao, C. J., Li, S., & Liu, Q. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.158031 · Cited by 10
Dual-Antibody Therapy in Advanced Colorectal Cancer: Gather Ye Rosebuds While Ye May
Blanke, C. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2522 · Cited by 10
A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer.
Weinberg, B. A., Marshall, J. L., Hartley, M. L., & Salem, M. E. (2016) · PubMed · Cited by 9
Self-citationOptimal duration of systemic treatment in metastatic colorectal cancer
Simkens, L. H. J., Koopman, M., & Punt, C. J. A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000087 · Cited by 9
Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice
Hurwitz, S. J., Zhang, H., Yun, S., Batuwangala, T. D., Steward, M., Holmes, S. D., Rycroft, D., Pan, L., Tighiouart, M., Shin, H. J. C., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1713-x · Cited by 9
Barni, S., Ghilardi, M., Borgonovo, K., Cabiddu, M., Zaniboni, A., & Petrelli, F. (2013) · Reviews on Recent Clinical Trials · doi:10.2174/15748871113089990042 · Cited by 9
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
